Search

everythinglearnresearchcommunity

for

Search:↓

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.

Parabens in Minoxidil are a concern for some users due to potential health risks. The conversation discusses the presence of methylparaben and propylparaben in a specific Minoxidil brand, Ylox.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

User reports hair loss improvement with twice-weekly 0.25mg Fin, twice-weekly Min, weekly 0.5mm microneedling, and daily massages. Unconventional regimen contradicts typical advice but may reduce side effects.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.

The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

Bimatoprost is discussed for hair and eyelash growth, with users confirming its legitimacy and availability from Indian pharmacies. It is noted that the common concentration may not be effective for significant scalp hair regrowth unless mixed with Minoxidil.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

Bimatoprost was discussed for hair loss, with concerns about long-term scalp effects. A user reported no substantial effect after 6 months of use.

Creatine does not interfere with minoxidil and microneedling for temple regrowth. Users discussed the effectiveness of these treatments.

The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

Microneedling promotes hair growth by increasing circulation and collagen production, with gains potentially lasting longer than those from minoxidil. Some users report sustained results after stopping microneedling, unlike with minoxidil and finasteride.

A user discussed a new hair loss treatment combining 5% Minoxidil with Bimatoprost 0.3mg/ml, applied once daily. They referenced a study suggesting Bimatoprost may be more effective than Minoxidil.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.